文献速递慢阻肺

厄多司坦对慢阻肺急性加重发生率和持续时间的影响:RESTORE研究

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
PubMed 文献 · Eur Respir J · 2017-10-12

RESTORE研究为前瞻性随机双盲安慰剂对照试验,纳入40-80岁GOLD II/III期慢阻肺患者445例,在常规治疗基础上加用厄多司坦300mg每日两次或安慰剂治疗12个月。结果显示厄多司坦使急性加重率降低19.4%(0.91 vs 1.13次/患者/年,p=0.01),主要归因于轻度加重率降低57.1%(0.23 vs 0.54,p=0.002),并使加重持续时间缩短24.6%(9.55 vs 12.63天,p=0.023)。

要点

  • 厄多司坦降低慢阻肺急性加重率19.4%,主要减少轻度加重。
  • 厄多司坦使急性加重持续时间缩短24.6%,不受严重程度影响。
  • 中重度加重率无显著差异(p=0.054),但趋势利于对照组。

核心结论

  • 在慢阻肺患者中,厄多司坦可降低急性加重的发生率和持续时间。

研究设计与样本

  • 前瞻性随机双盲安慰剂对照研究,纳入445例40-80岁GOLD II/III期慢阻肺患者,厄多司坦300mg每日两次或安慰剂治疗12个月。

主要发现

  • 厄多司坦使急性加重率降低19.4%(0.91 vs 1.13次/患者/年,p=0.01)。
  • 轻度加重率降低57.1%(0.23 vs 0.54次/患者/年,p=0.002)。
  • 中重度加重率无显著差异(0.68 vs 0.59次/患者/年,p=0.054)。
  • 加重持续时间缩短24.6%(9.55 vs 12.63天,p=0.023)。
  • 患者和医生主观严重度评分改善(p=0.022和p=0.048),缓解药物使用减少(p<0.001)。

关键数值与推荐

  • 厄多司坦300mg每日两次,治疗12个月。
  • 主要结局为研究期间急性加重次数。

临床怎么用

  • 对于GOLD II/III期慢阻肺患者,可考虑加用厄多司坦以减少急性加重频率和缩短持续时间。

局限性

  • 中重度加重率无显著差异,且趋势利于对照组。
  • 圣乔治呼吸问卷评分和首次加重时间无显著影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged 40-80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III. Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 months. The primary outcome was the number of acute exacerbations during the study.In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory volume in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91 versus 1.13 exacerbations·patient-1·year-1 for erdosteine and placebo, respectively; p=0.01), due to an effect on mild events; the reduction in the rate of mild exacerbations was 57.1% (0.23 versus 0.54 exacerbations·patient-1·year-1 for erdosteine and placebo, respectively; p=0.002). No significant difference was observed in the rate of moderate and severe exacerbations (0.68 versus 0.59 exacerbations·patient-1·year-1 for erdosteine and placebo, respectively; p=0.054) despite a trend in favour of the comparison group. Erdosteine decreased the exacerbation duration irrespective of event severity by 24.6% (9.55 versus 12.63 days for erdosteine and placebo, respectively; p=0.023). Erdosteine significantly improved subject and physician subjective severity scores (p=0.022 and p=0.048, respectively), and reduced the use of reliever medication (p<0.001), but did not affect the St George's Respiratory Questionnaire score or the time to first exacerbation.In patients with COPD, erdosteine can reduce both the rate and duration of exacerbations. The percentage of patients with adverse events was similar in both the placebo and erdosteine treatment groups.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017. PMID: 29025888. doi:10.1183/13993003.00711-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。